My watch list  

383 Current news of Merck


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Merck and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19

Company will focus on process development and improvements for manufacturing Baylor’s Covid-19 vaccine candidates


Merck and Baylor College of Medicine, Houston, Texas, USA, announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, designed to accelerate transition to Phase 1 clinical trials. “Vaccine manufacturing is extremely complicated, so we are ...


image description
Merck Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity

New, € 100 million facility will more than double existing production capacity


Merck announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, €100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the ...


image description
Merck Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine Manufacturing

Joint team reduced process development time to two months from a year


Merck and The Jenner Institute announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a ...


Merck Awarded Second U.S. Patent for CRISPR Gene-Editing Technology

CRISPR-chrom technology improves access to genome for more efficient editing


Merck announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology. With this allowance, Merck is the only provider with a patent covering the fusion of chromatin modulating peptides to CRISPR proteins, helping to clear chromatin out of ...


Merck Meets all Financial Targets and Makes Significant Strategic Progress


Merck met all its financial targets and thus grew profitably in fiscal 2019. At the same time, Merck also made significant progress in executing its strategic agenda. “We delivered on our promise and achieved growth for all our key performance indicators, namely net sales, EBITDA pre and EPS pre. ...


image description
3D printing of tablets

Merck and AMCM cooperate


Merck and AMCM, Starnberg, Germany, announced a cooperation agreement on the 3D printing of tablets. AMCM offers customized additive manufacturing solutions. The cooperation targets GMP-conform (Good Manufacturing Practice) tablet formulation development and production for clinical trials in a ...


Merck Divests Allergopharma to Dermapharm


Merck signed an agreement to sell its allergy business Allergopharma to Dermapharm Holding SE. The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions. Since 2007, Merck has made ...


image description
Merck to manufacture liquid biopsy kits for Swedish start-up

Liquid biopsy kits aim to improve accuracy of cancer diagnosis


Merck announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits. The kits analyze metabolites deregulated in several cancer types, making diagnoses more accurate. “Both small and large ...


image description
Merck Invests in State-Of-The-Art Biotech Development Facility in Switzerland


Merck announced an investment of €250million in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies. Driven by the growth of the Healthcare business sector R&D pipeline, this investment ...


image description
Merck Licenses Foundational CRISPR Integration Technology to Promega


Merck announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, USA access to Merck’s foundational CRISPR intellectual property. Promega will use Merck’s CRISPR genome-editing technology to create research products ...


Page 1 From 39
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE